COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,627 Articles (22,913 medRxiv, 8,714 bioRxiv)

Most recent first Previous |  Page 1373: Articles 13721-13730  | Next

Identification and Characterization of novel mutants of Nsp13 Protein among Indian SARS-CoV-2 isolates.
Kumari, D., Kumari, N., Kumar, S., Sinha, P. K., Shahi, S. K., Biswas, N. R., Kumar, A.
10.1101/2021.07.30.454406 — Posted: 2021-07-30
3D printed cobalt-chromium-molybdenum porous superalloy with superior antiviral activity
Arjunan, A., Robinson, J., Baroutaji, A., Marti, M., Tunon-Molina, A., Serrano-Aroca, A.
10.1101/2021.07.29.454385 — Posted: 2021-07-30
Diagnostic performance of a novel digital immunoassay (RapidTesta SARS-CoV-2): a prospective observational study with 1,127 nasopharyngeal samples
Suzuki, H., Akashi, Y., Ueda, A., Kiyasu, Y., Takeuchi, Y., Maehara, Y., Ochiai, Y., Okuyama, S., Notake, S., Nakamura, K., Ishikawa, H.
10.1101/2021.07.26.21261162 — Posted: 2021-07-30
Can Vaccine Prioritization Reduce Disparities in Covid-19 Burden for Historically Marginalized Populations?
Rosenstrom, E., Mele, J. A., Ivy, J., Mayorga, M., Patel, M., Hassmiller Lich, K., Johnson, K. D., Delamater, P., Keskinocak, P., Boyce, R., Smith, R., Swann, J. L.
10.1101/2021.07.27.21261210 — Posted: 2021-07-30
A method for the generation of pseudotyped virus particles bearing SARS coronavirus spike protein in high yields
Fujioka, Y., Kashiwagi, S., Yoshida, A., Satoh, A. O., Fujioka, M., Amano, M., Yamauchi, Y., Ohba, Y.
10.1101/2021.07.30.454063 — Posted: 2021-07-30
Photosensitized Electrospun Nanofibrous Filters for Capturing and Killing Airborne Coronaviruses under Visible Light Irradiation
Shen, H., Zhou, Z., Wang, H., Zhang, M., Han, M., Shen, Y., Shuai, D.
10.1101/2021.07.29.454404 — Posted: 2021-07-30
Overlapping Time Scales Obscure Early Warning Signals for the Second COVID-19 Wave
Dablander, F., Heesterbeek, H., Borsboom, D., Drake, J. M.
10.1101/2021.07.27.21261226 — Posted: 2021-07-30
Estimation of the onset rate and the number of asymptomatic patients of COVID-19 from the proportion of untraceable patients
Odagaki, T.
10.1101/2021.07.28.21261241 — Posted: 2021-07-30 Discussion: Onsite
Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
Maeda, K., Amano, M., Uemura, Y., Tsuchiya, K., Matsushima, T., Noda, K., Shimizu, Y., Fujiwara, A., Takamatsu, Y., Ichikawa, Y., Nishimura, H., Kinoshita, M., Matsumoto, S., Gatanaga, H., Yoshimura, K., Oka, S., Mikami, A., Sugiura, W., Sato, T., Yoshida, T., Shimada, S., Mitsuya, H.
10.1101/2021.07.27.21261237 — Posted: 2021-07-30
Association between COVID-19 infection rates by region and implementation of non-pharmaceutical interventions: A cross-sectional study in Japan
Anan, T., Ishimaru, T., Hino, A., Nagata, T., Tateishi, S., Tsuji, M., Ogami, A., Matsuda, S., Fujino, Y., for the CORoNaWork project
10.1101/2021.07.26.21261107 — Posted: 2021-07-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).